High-Purity Methylene Blue Process for N-Nitroso-Azure B Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methylene blue synthesis processes result in contamination by metal impurities and organic impurities such as Azure A-C and N-nitroso-Azure B, which are difficult to remove due to the chemical analogy and sequestering effect of the diaminophenothiazinium structure, limiting its use in medical applications.
Innovation Solution
A process to produce methylene blue with reduced N-nitroso-Azure B content by using a one-pot synthesis involving a reducing agent and a protective agent, followed by oxidation with a stable free radical agent, without the need for sequestering agents, resulting in a highly pure form with less than 0.7 ppm of N-nitroso-Azure B and overall impurity content below 3%.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional synthesis processes are used to produce methylene blue, then production cost and complexity are reduced, but metal impurities and organic impurities (including N-nitroso-Azure B) are generated that limit medical use
Solution Approach 1:
The synthesis process is divided into distinct stages: reductive alkylation stage (forming leuco-methylene blue intermediate) and oxidation stage (forming final methylene blue product). This segmentation allows for better control of impurity formation at each stage, particularly limiting N-nitroso-Azure B formation during the reductive alkylation phase while maintaining process efficiency.
Solution Approach 2:
The process controls critical parameters including pH (maintained between 4-7 during reductive alkylation), temperature (0-25°C during reductive alkylation, 25-50°C during oxidation), and reagent addition rates. These parameter changes optimize the formation of pure methylene blue while minimizing impurity generation, achieving pharmaceutical-grade purity without excessive process complexity.
2Manufacturing precision
If purification steps are added to remove N-nitroso-Azure B and other impurities, then purity of methylene blue is improved, but production time and cost increase
Solution Approach 1:
The process performs preliminary impurity prevention by controlling the reductive alkylation conditions to minimize N-nitroso-Azure B formation from the start. By maintaining pH 4-7 and using controlled addition of nitrosating agents, the impurity is prevented rather than requiring extensive downstream purification, thus maintaining high productivity.
Solution Approach 2:
The process converts the potential harm of N-nitroso-Azure B formation into a benefit by using controlled nitrosation conditions that actually help drive the desired reductive alkylation reaction forward while limiting excessive nitrosation. The controlled presence of nitrosating agents under specific pH conditions promotes the formation of the desired leuco-methylene blue intermediate without generating excessive impurities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves methylene blue with high purity (>95%) and reduced metal content within Pharmacopoeia limits, effectively eliminating N-nitroso-Azure B and other impurities, enhancing its suitability for medical use.
Implementation Method 1
adding a reducing agent to a starting phenothiazine compound or to a starting phenothiazinium compound
Implementation Method 2
oxidizing the leuco base thus obtained by adding a stable free radical agent
Data Source
AI summary
A highly pure methylene blue is disclosed, as well as a process for preparation and a pharmaceutical composition thereof. In particular, the invention relates to highly pure methylene blue essentially free of impurity N-Nitroso-Azure B. It is also described a methylene blue essentially free of other impurities, such as N-nitrosamines and potentially genotoxic impurities. Additionally it is disclosed the use of said highly pure methylene blue in the treatment of methemoglobinemia. Moreover, it is disclosed a method of analysis to determine the level of N-nitroso-Azure B in the methylene blue or in a pharmaceutical composition comprising the same.